Dr. Barry Dworkin

Mouse study using MS drug shows reduction in PTSD-like responses

Madely Health Headlines Commentary for May 27, 2014

Source:

Multiple sclerosis drug shows promise in treating post-traumatic stress disorder

Reference:

Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory

Related posts:

  1. Mountie's logic about right to smoke medical marijuana falls short
  2. Ontario law will recognize PTSD risk for first responders
  3. Ottawa’s first safe-injection site approved by Health Canada
  4. DNA testing to determine best choice of antidepressant not yet ready for clinical use. Data to be released in 2019 regarding test’s efficacy and patient outcomes.